Accurate FDA approval probability predictions. Free ODIN tiers, Pro full scores, Elite complete trading system.
Essential biotech tools for casual investors
Full ODIN scores, alerts, CSV exports
14-day money-back guarantee · Cancel anytime
Complete trading system + API + dashboards
14-day money-back guarantee · Cancel anytime
| Feature | Free | Pro | Elite |
|---|---|---|---|
| PDUFA Calendar | ✓ | ✓ | ✓ |
| ODIN Tier Assignments | ✓ | ✓ | ✓ |
| Full ODIN Scores (0-100%) | – | ✓ | ✓ |
| Signal Analysis | – | ✓ | ✓ |
| Email Alerts | – | ✓ | ✓ |
| Data Exports (CSV/JSON) | – | ✓ | ✓ |
| API Access | – | Basic | ✓ |
| Runup Strategy Tools | – | Limited | ✓ |
| Regime Detection | – | – | ✓ |
| Revenue Impact Scoring | – | – | ✓ |
| Historical Backtests (1999-2026) | – | – | ✓ |
| Priority Support | – | Slack + Calls |
Other PDUFA trackers give you dates. We give you AI-scored probabilities, options flow intelligence, and SHA-256 verified predictions — most of it free.
| Feature | PDUFA.BIO | BioPharmCatalyst | MarketBeat | FDAzilla |
|---|---|---|---|---|
| PDUFA Calendar | Free | $29/mo | Free (limited) | $15/mo |
| AI Approval Probability | ODIN ML (96.2%) | None | None | None |
| Options Flow Analysis | Pro ($19/mo) | None | None | None |
| SHA-256 Verified Predictions | Yes | No | No | No |
| Historical Backtest Data | Elite ($39/mo) | None | None | None |
| Runup Strategy Tools | Elite | None | None | None |
| Revenue Impact Scoring | Elite | None | None | None |
| API Access | Pro/Elite | $49/mo | None | None |
| Email Alerts | Pro | $29/mo | $25/mo | $15/mo |
| Real-Time Webhooks | Elite | None | None | None |
“ODIN called VNDA TIER_1 three weeks before approval. I entered at $4.80, sold at $6.91. That one trade paid for 9 years of Pro.”
— Retail trader · r/pennystocks
“The options flow data is what sets this apart. Seeing whale positioning shift 10 days before PDUFA gave me conviction to size up.”
— Active biotech trader · StockTwits
“We integrated the Elite API into our event-driven quant strategy. The ODIN scores provide a measurable alpha signal on PDUFA events.”
— Quantitative analyst · Institutional subscriber
ODIN (Outcome Determination Intelligence Network) is a machine-learning model trained on 2,210+ historical FDA PDUFA outcomes. It analyzes 45 featureed signals—including clinical efficacy, safety profiles, regulatory designations, sponsor track record, and competitive landscape—to estimate approval probability for upcoming drug decisions. The model assigns each PDUFA catalyst to one of four tiers: TIER_1 (85%+ approval), TIER_2 (65-85%), TIER_3 (40-65%), and TIER_4 (below 40%). Pro and Elite subscribers receive exact probability scores; Free users see only tier assignments.
Yes. Pro and Elite subscriptions are month-to-month with no long-term commitment. You can cancel at any time before your renewal date. Your subscription will remain active through the end of the current billing period. We also offer a 14-day money-back guarantee if you're not satisfied with your subscription.
Pro subscribers can export catalyst data in CSV format, including ODIN scores, approval probabilities, dates, and therapeutic area classifications. Elite subscribers get unlimited JSON/CSV exports, historical backtest data, and full API access with webhooks for real-time event notifications. All data is updated daily as FDA accepts new applications and assigns PDUFA dates.
ODIN achieves 96.2% all-time accuracy across 51 verified outcomes (as of February 2026), with 0.9193 AUC walk-forward testing. In February 2026 alone, ODIN correctly predicted all three PDUFA outcomes: ETON (approved), REGN (approved), and VNDA (approved). All predictions are SHA-256 hashed before the PDUFA date for independent verification. Review our detailed track record at /odin-track-record. Note that past performance does not guarantee future results.
PDUFA dates are free everywhere — including here. Pro gives you what nobody else has: AI probability scores from a model that called VNDA +44%, EXEL +38%, and achieved 96.2% all-time accuracy. The dates are the commodity; the ODIN score is the edge. One correct TIER_1 call on a $5K position averages +$2,200 in gains — paying for over 9 years of Pro.
BioPharmCatalyst and MarketBeat provide PDUFA calendars — but no AI scoring, no approval probability predictions, and no options flow analysis. PDUFA.BIO is the only platform combining machine-learning approval probability (ODIN), real-time options flow intelligence (put/call ratios, whale bias, unusual activity detection), historical runup backtesting, and SHA-256 verified predictions. The free tier alone matches what competitors charge for.
ODIN revenue tiers estimate the commercial impact of drug approval on the sponsoring company stock. R1 (blockbuster, $1B+ peak sales) typically produces 25-80% post-approval gains. R2 (significant, $500M-$1B) averages 15-40% gains. R3 (moderate, $100M-$500M) averages 8-20% gains. R4 (niche, under $100M) averages 3-12% gains. Elite subscribers receive revenue tier scoring with position multiplier suggestions for catalyst sizing.
No. PDUFA.BIO provides data, statistical analysis, and machine-learning predictions for educational and informational purposes. ODIN scores represent probability estimates based on historical patterns, not trading recommendations. Always consult a licensed financial advisor before making investment decisions. See our full disclaimer at /disclaimer.
Pro and Elite subscribers receive automated email alerts at T-25, T-14, T-7, and T-5 days before each PDUFA date. Alerts include the ODIN score, tier assignment, recent options flow data, and a brief catalyst summary. Elite subscribers can customize alert timing and add webhook integrations for automated trading systems.
ODIN options flow tracks put/call ratios, unusual options activity (UOA), institutional whale positioning, and implied volatility changes around PDUFA dates. It calculates an Options Pressure score (0-100), Whale Bias (-100 to +100), and Vol Shock indicator. This data helps identify when smart money is positioning ahead of FDA decisions. Pro users see summary signals; Elite users get full strike-level chain data.
Yes. Pro subscribers get basic API access (100 requests/day) for pulling ODIN scores, PDUFA dates, and catalyst data in JSON format. Elite subscribers get full API access (unlimited requests), webhook event notifications, and historical backtest endpoints. API documentation is available at /api-access after subscribing.
Before each PDUFA date, ODIN publishes a SHA-256 cryptographic hash of its prediction. After the FDA decision, the original prediction text is revealed and anyone can verify it matches the pre-published hash. This proves predictions were made before outcomes were known — no hindsight bias. All hashes are recorded on our data provenance page at /data-provenance.
PDUFA calendar data is updated daily as the FDA publishes new target action dates. ODIN scores are recalculated when material information changes (new clinical data, advisory committee votes, manufacturing inspections). Options flow data updates every 5 minutes during market hours. Historical backtest data is refreshed quarterly.
Yes. We offer 50% off Pro for verified students and academic researchers. Contact support with your .edu email address for the discount code. Academic institutions can also inquire about bulk licensing for classroom use.
We accept all major credit and debit cards (Visa, Mastercard, American Express, Discover) through Stripe. Annual plans are also available at a 17% discount. All transactions are processed securely and we never store your full card details.
Important: PDUFA.BIO is not the FDA. ODIN scores are ML model outputs, not financial advice. All investing carries risk. Read full disclaimer →
Start free with full calendar access and ODIN scores. Upgrade for deep signal analysis, email alerts, and the complete runup trading system.
FDA catalyst intelligence powered by the ODIN v1108 scoring engine. Trained on 2,200+ PDUFA decisions & 2,000+ phase readouts (2015–2026).
PDUFA.BIO is the data-driven FDA PDUFA calendar and biotech catalyst calendar built for quantitative investors. Track upcoming PDUFA dates for 2026, FDA drug approval action dates, and biotech earnings dates in a unified, filterable calendar. Learn what a PDUFA date is and how the ODIN AI scoring engine generates FDA approval probability scores. Use the biotech catalyst screener to filter by ticker, therapeutic area, and ODIN tier. Explore the PDUFA runup strategy and verify ODIN's accuracy on the verified track record page. Browse our biotech glossary and catalyst research hub.
DISCLAIMER: PDUFA.BIO is not affiliated with, endorsed by, or connected to the U.S. Food & Drug Administration (FDA) or any government agency. The name "PDUFA" refers to the Prescription Drug User Fee Act and is used descriptively. This site does not provide financial, investment, legal, or medical advice. PDUFA.BIO is not a registered investment advisor, broker-dealer, or financial planner. Probability scores are generated by machine-learning models based on historical data and publicly available information. These scores are statistical estimates, not predictions or guarantees of FDA action or securities performance. Past approval rates do not guarantee future results.
RISK WARNING: Investing in biotechnology and pharmaceutical securities involves substantial risk, including the risk of total loss of capital. Binary catalyst events (such as PDUFA dates) can result in extreme price volatility. You should not invest money you cannot afford to lose. Always consult with a qualified financial advisor before making investment decisions. PDUFA.BIO, its operators, contributors, and affiliates accept no responsibility or liability for any losses arising from use of this site.